Toggle navigation
Home
Search
Services
Blog
Contact
About
Broadly Rsv Neutralizing Human Monoclonal Antibodies
Brams, Peter
Idec Pharmaceuticals Corporation, San Diego, CA, United States
Search 10 grants from Peter Brams
Search grants from Idec Pharmaceuticals Corporation
Share this grant:
:
:
Abstract
Funding
Institution
Related projects
Comments
Recent in Grantomics:
Ohio State University
vs. funders. Who wins?
Read more...
How should you pick the next fundable research topic?
Read more...
Recently viewed grants:
Mechanisms of islet transplant immune tolerance
HIV Risk Reduction and Drug Abuse Treatment in Malaysia
Sphingolipids and Map Kinases
Regulatory Mechanism of Renal Microcirculation
NMR Study of Liver Intoxication with Alcohol and Related Compounds
Recently added grants:
BLR&D Research Career Development Transition Award Application
Opioid Support and Risk Reduction Online Platform
Regulation of pancreatitis severity
Mechanisms of Renal Cell Injury
The mechanism of cardio-protection from a sulfonylurea receptor isoform 2 splice variant (SUR2A-55) and its role in regulating ROMK activity, the putative mitochondrial ATP sensitive potassium channel
Abstract
Funding Agency
Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44AI036027-02A1
Application #
2072058
Study Section
Special Emphasis Panel (ZRG7-SSS-4 (02))
Project Start
1994-08-15
Project End
1998-04-30
Budget Start
1996-05-01
Budget End
1997-04-30
Support Year
2
Fiscal Year
1996
Total Cost
Indirect Cost
Institution
Name
Idec Pharmaceuticals Corporation
Department
Type
DUNS #
City
San Diego
State
CA
Country
United States
Zip Code
92121
Related projects
NIH 1997
R44 AI
Broadly Rsv Neutralizing Human Monoclonal Antibodies
Brams, Peter / Idec Pharmaceuticals Corporation
NIH 1996
R44 AI
Broadly Rsv Neutralizing Human Monoclonal Antibodies
Brams, Peter / Idec Pharmaceuticals Corporation
Comments
Be the first to comment on Peter Brams's grant